A short guide to the menopause transition
Menopause is a single point in time: the day twelve months after your last period, counted backwards. The years of change leading up to it are perimenopause (the menopause transition), and the years after it are postmenopause. Most symptoms begin in perimenopause, often while you are still having periods. This framing follows STRAW+10, the international reference standard that stages reproductive ageing from your cycle pattern and symptoms (Harlow et al., 2012).
For most women, menopause is a clinical diagnosis based on age and symptoms, not a blood test. The NICE guideline (NG23, 2024) is explicit: if you are 45 or over, perimenopause is identified from new symptoms plus changing periods, and menopause from twelve period-free months, with no lab test needed. Hormones like FSH swing day to day in perimenopause, so a single test can read normal one week and menopausal the next. Blood tests have a clear role mainly under 45, or under 40 if early menopause is suspected.
This tool is an educational self-assessment, not a diagnosis. It organises 14 symptoms across five areas and estimates a likely STRAW+10 stage from your cycle history. The symptom areas and the 0 to 4 scoring are modelled on validated questionnaires such as the Menopause Rating Scale (Heinemann et al., 2004). The validated instruments are exactly that, validated; our descriptive result bands are not a clinical cut-off, they are there to help you reflect and to give you better words for a conversation with a clinician.
Use your result as a structured starting point. If symptoms affect your sleep, mood, work, relationships or quality of life, that alone is reason enough to talk to a doctor, there is no score you need to reach first. If the test flags something urgent, like bleeding after menopause or symptoms before 40, please act on it. Effective, evidence-based options exist for almost every symptom of this transition, and the right choice is one you make together with a clinician who knows your history.
Your menopause questions, answered
Perimenopause is the transition, when periods become irregular and symptoms like hot flushes often start, and you can still get pregnant. Menopause is a single point: twelve months in a row with no period and no other cause. Everything after that is postmenopause (NICE NG23; Harlow et al., 2012).
Perimenopause commonly lasts about four to eight years, but it varies widely. The transition usually begins in the mid to late 40s, with menopause itself around age 51 on average in Europe, and postmenopause then lasts the rest of your life.
Your stage is judged mainly from your cycle pattern plus your symptoms, which is what STRAW+10 uses and what this self-assessment estimates (Harlow et al., 2012). A blood test usually cannot pin down your stage during perimenopause because levels fluctuate too much. Tracking your cycles and symptoms over a few months tells you more than any single test.
If you are 45 or over, guidelines advise against using FSH to diagnose menopause, because the diagnosis is clinical (NICE NG23). FSH testing has a real role only at 40 to 45 with symptoms and cycle changes, or under 40 where early menopause is suspected. Ask your clinician whether a test would actually change anything for you.
No, it is an educational self-assessment, not a diagnosis, and it does not replace a clinician. Its symptom areas and 0 to 4 scoring draw on the validated Menopause Rating Scale, and its staging on STRAW+10, but the descriptive result bands we show are not themselves a validated diagnostic cut-off. Treat the result as a conversation starter.
The classic ones are hot flushes and night sweats, disturbed sleep, mood changes, brain fog, joint and muscle aches, weight changes around the middle, and vaginal or urinary symptoms. Hot flushes last longer than many expect: in the large SWAN study, women with frequent symptoms had them for a median of about 7 years, and more than 11 years for some, often continuing several years after the final period (Avis et al., 2015). Duration varies a lot between individuals.
Seek prompt advice for any vaginal bleeding after menopause, that is after twelve period-free months, or unusual bleeding between periods or after sex, which always needs checking. Also see someone promptly for menopause-type symptoms before age 40, or for severe low mood, hopelessness or thoughts of self-harm. These are not just menopause until a professional has checked.
Menopause before 45 is called early menopause, and before 40 it is premature ovarian insufficiency (POI), which affects roughly 1 in 100 women under 40. In under-40s it is diagnosed from symptoms plus a raised FSH on two tests several weeks apart (NICE NG23). It matters because earlier loss of estrogen raises long-term bone and heart risk, so it usually warrants specialist care and treatment until around the usual age of menopause.
For most women, no. Long-term data from the SWAN study found that the dip in processing speed and memory during perimenopause was temporary and tended to recover afterwards, rather than keep declining (Greendale et al., 2009). Brain fog is real and frustrating but is generally time-limited and is not a marker of dementia. Persistent or worsening memory problems should still be discussed with a clinician.
A lot. Regular exercise, good sleep habits, limiting alcohol and managing triggers all help, and menopause-specific cognitive behavioural therapy (CBT) is recommended (NICE NG23); for hot flushes it mainly reduces how bothersome they feel and improves coping, mood and sleep, with a smaller effect on how often they occur. Some non-hormonal medicines also exist. A clinician can match options to your symptoms and preferences.
Menopausal hormone therapy replaces estrogen (with a progestogen if you have a uterus) and is the most effective treatment for hot flushes and night sweats (NICE NG23; The Menopause Society, 2022). For most healthy women under 60 or within 10 years of menopause, the benefits generally outweigh the risks, the so-called timing window. It is a personal decision made with a clinician based on your symptoms, health and family history.
The picture is more nuanced than the headlines. Estrogen-only therapy, for women without a uterus, is not associated with, and may slightly lower, breast-cancer risk, while combined estrogen plus progestogen carries a small increase that grows with longer use (The Menopause Society, 2022). The absolute increase is small and is weighed against the benefits. This is a debated area, so discuss your personal risk with a clinician.
For some risks, current evidence suggests so. Transdermal estrogen (patch or gel) and lower doses may carry a lower risk of blood clots and stroke than estrogen tablets (The Menopause Society, 2022). This is one reason patches and gels are often preferred, especially with clotting or cardiovascular risk factors. The route should be chosen with your clinician.
No. HRT is not recommended for preventing heart disease (NICE NG23). It is prescribed for symptom relief and quality of life, not as heart protection. Protect your heart the usual evidence-based ways: not smoking, physical activity, and managing blood pressure and cholesterol with your clinician.
Genitourinary syndrome of menopause (GSM) is the accurate modern term for vaginal dryness, irritation, pain during sex and urinary symptoms caused by falling estrogen (Portman and Gass, 2014). Unlike hot flushes, it tends to be progressive and persistent without treatment. Moisturisers, lubricants and low-dose vaginal estrogen are the mainstays.
Low-dose vaginal estrogen has very little absorption into the body and is considered safe and effective for GSM, and it can be used long term (The Menopause Society, 2022). For breast-cancer survivors it may be considered for bothersome symptoms that non-hormonal options do not fix, in consultation with the oncology team, especially for anyone on aromatase inhibitors. This is a shared decision with your doctors.
This is biology, not just willpower. As estrogen falls, fat shifts toward the abdomen while women lose lean muscle during the transition, changes seen clearly in the SWAN cohort and not captured by the scale alone. The newer idea of the musculoskeletal syndrome of menopause groups muscle and bone loss, joint pain and related changes as estrogen-driven (Wright et al., 2024).
Resistance and impact training is the standout: in the LIFTMOR trial, supervised high-intensity resistance and impact training improved bone density at the spine and hip in postmenopausal women with low bone mass, safely (Watson et al., 2018). Enough protein supports muscle, and adequate calcium and vitamin D support bone, but in healthy, well-nourished women routine supplements have not been shown to prevent fractures; they help most if you are deficient or at higher risk. Build up gradually, ideally with guidance.
Risk of both does rise around and after menopause as estrogen's protective effects fade, and more so when menopause is early or premature. Bone loss speeds up in the years around the final period, raising fracture risk over time. Menopause is one contributor among many, alongside age, genetics, blood pressure and lifestyle, and a natural menopause at the usual age is a normal life stage, not a disease.
The evidence is weak and inconsistent. A Cochrane review found no significant difference between black cohosh and placebo for hot flushes, and results for soy and other phytoestrogens are mixed. Natural does not mean risk-free or free of drug interactions, so tell your clinician about anything you take.
Your answers are processed in your browser to generate your result on screen. Nothing you enter is saved to your account or sent to a server, and the test needs no sign-up. You can close or restart it at any time and nothing is kept.
Classic instruments like the Menopause Rating Scale focus on symptom severity. This tool keeps that 0 to 4 logic but adds three things they leave out: a STRAW+10 stage estimate from your cycle history, red-flag routing for things that need a doctor now, and a longevity layer on bone, heart and exercise. It is still educational, not diagnostic.
The research behind this test, and why we use it
We wrote our own questions, informed by validated instruments and the peer-reviewed literature. Here is each main source and the part of the test it supports. The instruments are validated; our descriptive result bands are not a clinical cut-off.
- Heinemann et al. (2004). The Menopause Rating Scale (MRS): a methodological review. Health Qual Life Outcomes 2:45.
A psychometric review of the validated MRS, which scores 11 symptoms 0 to 4 across somatic, psychological and urogenital domains. It is the model for our 0 to 4 symptom scoring; our domain grouping and band cut-offs are our own pragmatic, descriptive scheme, not a validated factor solution inherited from it.
- Harlow et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10 (STRAW+10). Menopause 19(4):387-395.
The international consensus that stages reproductive ageing from cycle criteria and defines menopause as twelve months of amenorrhea. It is the direct basis for our staging questions and the stage estimate the test produces from your menstrual history.
- NICE NG23 (2024 update). Menopause: identification and management.
The UK clinical guideline on diagnosis, symptoms, HRT and non-hormonal options. It anchors our key messages: menopause is diagnosed clinically without blood tests over 45, the limited role of FSH, the red flags, CBT as an option, and that HRT is for symptoms, not heart-disease prevention.
- The Menopause Society (NAMS) (2022). Hormone Therapy Position Statement. Menopause 29(7):767-794.
The leading evidence-based position on hormone therapy: the timing window, the breast-cancer nuance (estrogen-only vs combined, and duration), transdermal and clot risk, and the safety of low-dose vaginal estrogen. It grounds our HRT and GSM answers, including the careful wording for breast-cancer survivors.
- AWMF S3-Leitlinie 015/062. Peri- und Postmenopause: Diagnostik und Interventionen.
The German-language S3 guideline for the DACH region, which aligns broadly with NICE and the Menopause Society and confirms hormone therapy as the most effective option for significant symptoms. It makes the content credible and consistent for German readers.
- Watson et al. (2018). High-Intensity Resistance and Impact Training (LIFTMOR RCT). J Bone Miner Res 33(2):211-220.
A randomised trial showing that twice-weekly supervised high-intensity resistance and impact training improved spine and hip bone density and function in postmenopausal women with low bone mass, safely. It is the evidence behind our bone and exercise advice, that loading the skeleton builds bone.
- Wright et al. (2024). The musculoskeletal syndrome of menopause. Climacteric.
A review proposing a unifying term for the estrogen-driven cluster of joint pain, muscle and bone loss in the transition. It underpins our body domain and the framing that midlife joint and muscle changes are part of menopause physiology, not random ageing.
- Greendale et al. (2009). Effects of the menopause transition on cognition (SWAN). Neurology 72(21):1850-1857.
A longitudinal SWAN analysis showing that the dip in processing speed and verbal memory during perimenopause recovered afterwards. It is the evidence for our brain-fog reassurance: real, but typically time-limited and not a dementia signal.
- Portman & Gass (2014). Genitourinary syndrome of menopause: new terminology. Menopause 21(10):1063-1068.
The consensus that introduced the term GSM to replace vulvovaginal atrophy, covering genital, sexual and urinary symptoms of estrogen loss. It defines and names our genitourinary domain and the language we use for vaginal and bladder symptoms.
- SWAN, the Study of Women's Health Across the Nation (incl. Avis et al., 2015, JAMA Intern Med 175(4):531-539).
The large, multi-ethnic longitudinal cohort behind much of what we know about real-world symptom timelines and body-composition change. It supplies our hot-flush duration figure (a median of about 7 years), the cognition-recovery story, and the muscle-loss and fat-redistribution evidence.